OhioHealth Vascular Institute OHVI RECOMMENDATIONS

Symptomatic Atherosclerotic Carotid Stenosis

AMAUROSIS FUGAX, HEMISPHERIC SYMPTOMS TIA OR STROKE

History and Physical, Screening Carotid Duplex; consider TTE with bubbles

Place an Inpatient Consult to Neurology for Pre Post NIHSS and MRS

OTHER:

Dizziness, seizure, syncope, non-hemispheric neurologic deficits not likely related to CAS consider other evaluation or neurology consultation

>50 % by catheter angiogram OR >70 % by duplex ultrasound confirmed with MR, CT or catheter angiogram

Revascularization decision for type of revascularization based on patient characteristics and physician/patient.

< 50 % by catheter angiogram OR < 70 % by duplex

Consult EP syncope evaluation

High Risk Features for CEA

- History of neck irradiation
- + History of ipsilateral CEA
- + History of tracheostomy or radical neck dissection
- + Anatomically high bifurcation
- + High cardiopulmonary risk Class III CHF or need for CABG valve

High Risk Features for CAS fem or TCAR

- + Carotid Tortuosity
 - Proximal = fem
 - Distal = fem TCAR
- + Difficult Arch = fem
- + Common carotid disease = TCAR
- + Circumferential dense calcium = fem TCAR
- + Unable to tolerate antiplatelet med = fem TCAR
- + Uncooperative patient dementia = fem TCAR no gen anesthesia
- + Recent CEA = fem TCAR
- + Contrast anaphylaxis = fem TCAR
- + Large adipose neck = TCAR
- + Dye anaphylaxis

ABCD 2 Stroke Risk Score

- + Age >60 = 1
- + BP 140 90 = 1
- + Unilateral weakness = 2
- + Speech disturbance without weakness = 1
- + >60 min symptom duration = 2
- + 10 59 min symptom duration = 1
- + <10 min symptom duration = 0
- + Presence of Diabetes = 1

Score 0 - 3: Low risk of stroke

Score 4 - 5: Moderate risk of stroke

Score 6 - 7: High risk of stroke

** Consider correction of stenosis in 3 7 days after presentation with TIA if score >4, with amaurosis as presenting symptom, correction can occur sooner.

Repair within 14 days if "Minor Ischemic Stroke Stroke" after Neuro consult.

Repair within 6 weeks if moderate to severely disabling stroke.

All treatment arms include optimal medical therapy defined by:

- + BP < 140 90 ACEi ARB first line
- + LDL < 100 70 for diabetics) statin preferred
- + Counseling for tobacco cessation
- + Antiplatelet therapy with Aspirin, Clopidogrel or ASA
- + Dypyrimadole
- + Diabetic management
- + Refer to Stroke Prevention Clinic



OHVI RECOMMENDATIONS | SYMPTOMATIC ATHEROSCLEROTIC CAROTID STENOSIS

ASYMPTOMATIC CAROTID STENOSIS Found during evaluation of non ischemic symptoms Found on screening exam dizziness, seizure, syncope, non hemispheric symptoms <50% by >50-69 % >70% (or 80%) by Duplex Duplex by Duplex criteria criteria criteria (EDV >100) Consider conservative medical therapy if age >80 and/or comorbid life expectancy <5 years. Conventional angiography, Optimal medical MR or CT Consider Optimal therapy and Medical therapy intermittent with every 6-12 surveillance for month Consider for change in Consider for elective surveillance Elective symptoms and repair if unable to progression of Repair tolerate optimal disease see medical therapy and/or surveillance if significant guidelines. progression of disease Place an Inpatient Consult to Neurology for Pre Post NIHSS and MRS Decision for type of revascularization based on patient characteristics, physician/patient discussion. All treatment arms include optimal medical therapy defined by: BP <140 90 ACEi ARB first line **High Risk Features for CAS** LDL <100 70 for diabetics) statin + Tortuosity **High Risk Features for CEA** preferred Difficult Arch ie Type III with History of neck irradiation Counseling for tobacco cessation atheromatous disease History of ipsilateral CEA Antiplatelet therapy with Aspirin, Circumferential dense calcium History of tracheostomy or Clopidogrel or ASA Dypyrimadole **Thrombus** radical neck dissection Diabetic management Unable to tolerate antiplatelet meds Anatomically high bifurcation Uncooperative patient dementia High cardiopulmonary risk Recent CEA Class III CHF or need for

CABG valve

Revised May 2020

Dye anaphylaxis